Abstract:Annals of Pharmacotherapy, Ahead of Print. Objective:To review the pharmacology, efficacy, safety, dosing and administration, and relevance to patient care and clinical practice of B-cell maturation antigen (BCMA) directed immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAb), for the management of relapsed/refractory multiple myeloma (RRMM).Data Sources:A literature review of PubMed (1966 to July 2024) was conducted using the keywords idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, elranatamab, and multiple myeloma. Data was also obtained from unpublished meeting abstracts and prescribing information.Study Selection and Data Extraction:All relevant published articles, unpublished abstracts, and prescribing information on anti-BCMA immunotherapies for the treatment of RRMM were reviewed.Data Synthesis:Idecabtagene vicleucel and ciltacabtagene autoleucel are BCMA-directed CAR-T cell therapies that have been compared to standard of care (SOC) regimens for MM in early relapse in the phase III trials KarMMa-3 and CARTITUDE-4, respectively. Both studies demonstrated a significantly improved in response rates, depth of response, and progression-free survival compared to SOC. BsAbs teclistamab and elranatamab have been evaluated in the phase II trials MajesTEC-1 and MagnetisMM-3, respectively. Overall response rates of 63 and 61% were observed with teclistamab and elranatamab, respectively, in a population of patients with heavily pretreated RRMM.Relevance to Patient Care and Clinical Practice in Comparison with Existing Drugs:BCMA-directed immunotherapies have demonstrated efficacy in the treatment of RRMM. Safety issues with BCMA-directed immunotherapies include cytokine release syndrome, neurotoxicity, infections, and cytopenias. Operational challenges and issues with access to care exist with these therapies as they may be limited to institutions with the infrastructure to safely administer and monitor patients for toxicities.Conclusion:BCMA-directed immunotherapies represent an important advancement in the management of RRMM and have significantly added to the available treatment options for this disease.

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting

Bispecific Antibody Treatment of Multiple Myeloma: Latest Updates from the 2022 ASH Annual Meeting

BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma

Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review

Non‐BCMA Targeted CAR‐T Cell Therapies for Multiple Myeloma

Beyond BCMA: Newer immune targets in myeloma

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting

BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma

BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them

BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events

B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice

[Targeting BCMA in Multiple Myeloma Using Chimeric Antigen Receptor-Engineered T Cells].

On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future

BCMA CAR-T cells in multiple myeloma–ready for take-off?

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

CT103A, a Forward Step in Multiple Myeloma Immunotherapies

The Exploration of B Cell Maturation Antigen Expression in Plasma Cell Dyscrasias Beyond Multiple Myeloma

Updates on CAR T cell therapy in multiple myeloma

Current Advances in Chimeric Antigen Receptor T-cell Therapy for Refractory/relapsed Multiple Myeloma.

Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth

Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma